Skip to main content
Clinical Trials/NCT02300090
NCT02300090
Completed
Not Applicable

A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD).

AstraZeneca1 site in 1 country161 target enrollmentOctober 26, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
AstraZeneca
Enrollment
161
Locations
1
Primary Endpoint
To detect a reduction in the rate of hospitalisations due to COPD exacerbations
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

A real world study to determine the effectiveness of a patient support service to aid COPD patients in their self management.

Detailed Description

The purpose of the study is to evaluate a digital health wellness support tool for patients in primary care with COPD using a smart mobile app, patient web portal and technology attached to the patients SABA reliever inhaler. Using the patients pre-defined COPD self management plan, the active arm of the study complete a daily diary (EXACT PRO) and record their daily SABA inhaler usage. After defining a health and symptom score baseline over a two week period, any significant deviations in SABA reliever use or daily diary scoring will alert patients that they may be having a change in their symptoms and advise them to refer to their self management plan and if they need to start their rescue medication. The primary outcome measure for the study is a 25% reduction in unplanned COPD hospital admissions (n=250 completing the study in each arm).

Registry
clinicaltrials.gov
Start Date
October 26, 2016
End Date
August 23, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of COPD
  • FEV1/FVC ratio \>0.3-\<0.7 and FEV1 \> 30% post-bronchodilator
  • Prescribed either ICS, LABA and or LAMA at dose for COPD
  • Exacerbations reported within the last 12 months requiring treatment with \>1 systemic steroid and/or antibiotics, OR hospitalisation within last 12 months due to exacerbation, OR have received \>12 SABA prescriptions in previous 12 months
  • Patient has a self management plan which includes use of an oral steroid at a dose within NICE guidelines, and additionally antibiotics as appropriate.

Exclusion Criteria

  • Symptomatic asthma or seasonal allergic rhinitis leading to hospitalisation in previous 12 months
  • Patients unable to use a mobile phone

Outcomes

Primary Outcomes

To detect a reduction in the rate of hospitalisations due to COPD exacerbations

Time Frame: Analysed over a twelve month timeframe

The mean number of COPD related hospitalisations per patient per year for patients who are receiving the digital service in the study will be compared to the rate of COPD related hospitalisations in patients receiving current best care alone over a twelve period.

Secondary Outcomes

  • To detect a reduction in the number of exacerbations requiring treament with antibiotics and or systemic steriods(12 months)
  • To detect an improvement in patients own perceived health status, as assessed by St Georges Respiratory Questionnaire-C(12 months)
  • To detect a reduction in the duration of hospitalisations due to COPD exacerbations.(12 months)

Study Sites (1)

Loading locations...

Similar Trials